Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematological changes in Down's syndrome.

D J Ganick

    Critical Reviews in Oncology/Hematology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Individuals with Down syndrome (DS) exhibit hematological abnormalities, including increased leukemia risk. The extra genetic material on chromosome 21 may confer a proliferative advantage to stem cells, predisposing them to leukemia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.

    Cancer·1995
    Same author

    Skin changes associated with hematologic and oncologic diseases in children.

    New York state journal of medicine·1992
    Same author

    Severe hematologic toxicity of valproic acid. A report of four patients.

    The American journal of pediatric hematology/oncology·1990
    Same author

    Thoracic neuroblastoma presenting as a cystic hygroma.

    Archives of disease in childhood·1988
    Same author

    Fine needle aspiration cytology of neuroblastoma, including peripheral neuroectodermal tumor, with immunocytochemical and ultrastructural confirmation.

    Acta cytologica·1988
    Same author

    Clinical utility of fine needle aspiration in the diagnosis and management of neuroblastoma.

    Medical and pediatric oncology·1988
    Same journal

    Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

    Critical reviews in oncology/hematology·2026
    Same journal

    DNA polymerase epsilon catalytic subunit (POLE) in cancer: implications for tumor biology and therapeutic strategies - a comprehensive review.

    Critical reviews in oncology/hematology·2026
    Same journal

    Long Non-Coding RNAs in Triple-Negative Breast Cancer: Emerging Drivers of Tumor Biology, Prognosis, and Drug Resistance.

    Critical reviews in oncology/hematology·2026
    Same journal

    Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

    Critical reviews in oncology/hematology·2026
    Same journal

    Gene Fusions in Non-small cell lung carcinoma (NSCLC): Expert Perspectives and Practical Considerations for routine testing.

    Critical reviews in oncology/hematology·2026
    Same journal

    Opportunities and Challenges of Dihydrodiol dehydrogenase Expression in Hepatocellular carcinoma.

    Critical reviews in oncology/hematology·2026
    See all related articles

    Area of Science:

    • Hematology
    • Genetics
    • Oncology

    Background:

    • Down syndrome (DS) is associated with numerous hematological abnormalities.
    • Hematological findings in newborns with DS, including transient leukemoid disorders, are of significant interest.
    • There is a known increased incidence and specific types of leukemia in individuals with DS.

    Purpose of the Study:

    • To review recent studies on hematological findings in Down syndrome.
    • To explore the link between the extra genetic material in chromosome 21 and hematological malignancies.
    • To discuss the immunological aspects and specific proliferative disorders in DS patients.

    Main Methods:

    • Review of recent scientific literature on Down syndrome and hematology.
    • Analysis of studies on chromosomal abnormalities and their impact on hematopoietic stem cells.

    Related Experiment Videos

  • Examination of data on leukemia incidence and types in DS patients.

    • Main Results:

    • Newborns with DS may present with transient leukemoid/leukemia-like disorders.
    • Individuals with DS have a higher incidence of leukemia, particularly specific types.
    • The extra genetic material on chromosome 21 appears to provide a proliferative advantage to hematopoietic stem cells, increasing leukemia risk.

    Conclusions:

    • The extra genetic material on chromosome 21 is implicated in the increased risk of leukemia in Down syndrome.
    • Megakaryocytic proliferative disorders are more prevalent in DS patients.
    • Further research into specific genetic loci on chromosome 21 may elucidate the mechanisms behind hematopoietic stem cell growth advantages and leukemia development.